Compare LXFR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | EBS |
|---|---|---|
| Founded | 1898 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.4M | 409.5M |
| IPO Year | 2002 | 2006 |
| Metric | LXFR | EBS |
|---|---|---|
| Price | $12.19 | $7.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 230.8K | ★ 716.6K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | 0.28 | ★ 0.93 |
| Revenue | $384,600,000.00 | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | $5.01 | N/A |
| P/E Ratio | $43.61 | ★ $8.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $4.02 |
| 52 Week High | $16.03 | $14.06 |
| Indicator | LXFR | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 34.58 |
| Support Level | $11.32 | $7.51 |
| Resistance Level | $12.71 | $9.28 |
| Average True Range (ATR) | 0.43 | 0.28 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 55.21 | 6.88 |
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.